Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salarius Pharmaceuticals ( (SLRX) ) has provided an update.
On July 28, 2025, Salarius Pharmaceuticals received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq’s Equity Standard and Minimum Bid Price Requirement by mid and late August 2025, respectively. Previously, Salarius faced potential delisting due to non-compliance with these standards, but the extension allows the company more time to meet the necessary criteria, impacting its market position and providing relief to stakeholders concerned about its Nasdaq listing status.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing cancer therapies. The company is involved in creating treatments that target specific cancer types, aiming to improve patient outcomes.
Average Trading Volume: 1,241,528
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.6M
For an in-depth examination of SLRX stock, go to TipRanks’ Overview page.